1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 14
2 Introduction 15
2.1 Ovarian Cancer Overview 15
3 Products under Development 16
3.1 Ovarian Cancer – Pipeline Products by Stage of Development 16
3.2 Ovarian Cancer – Pipeline Products by Territory 17
3.3 Ovarian Cancer – Pipeline Products by Regulatory Path 18
3.4 Ovarian Cancer – Pipeline Products by Estimated Approval Date 19
3.5 Ovarian Cancer – Ongoing Clinical Trials 20
4 Ovarian Cancer – Pipeline Products under Development by Companies 21
4.1 Ovarian Cancer Companies – Pipeline Products by Stage of Development 21
4.2 Ovarian Cancer – Pipeline Products by Stage of Development 25
5 Ovarian Cancer Companies and Product Overview 29
5.1 2cureX AB Company Overview 29
5.1.1 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview 29
5.2 A&G Pharmaceutical Inc Company Overview 30
5.2.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 30
5.3 AB ANALITICA srl Company Overview 31
5.3.1 AB ANALITICA srl Pipeline Products & Ongoing Clinical Trials Overview 31
5.4 Accudava Inc Company Overview 32
5.4.1 Accudava Inc Pipeline Products & Ongoing Clinical Trials Overview 32
5.5 Adaptive Biotechnologies Corp Company Overview 34
5.5.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 34
5.6 Almac Diagnostic Services Ltd Company Overview 35
5.6.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 35
5.7 Angle Biosciences Inc Company Overview 38
5.7.1 Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Anixa Diagnostics Corporation Company Overview 39
5.8.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 39
5.9 AroCell AB Company Overview 44
5.9.1 AroCell AB Pipeline Products & Ongoing Clinical Trials Overview 44
5.10 Arrayit Corporation Company Overview 45
5.10.1 Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 45
5.11 Aspira Labs Company Overview 46
5.11.1 Aspira Labs Pipeline Products & Ongoing Clinical Trials Overview 46
5.12 Aurelium BioPharma Inc. Company Overview 50
5.12.1 Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
5.13 Avant Diagnostics Inc Company Overview 53
5.13.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 53
5.14 Ayanda Biosystems SA (Inactive) Company Overview 54
5.14.1 Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 54
5.15 BARD1 Life Sciences Ltd Company Overview 55
5.15.1 BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 55
5.16 Becton Dickinson and Co Company Overview 56
5.16.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 56
5.17 BioFluidica Microtechnologies LLC Company Overview 57
5.17.1 BioFluidica Microtechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview 57
5.18 Bioindustry Park Silvano Fumero SpA Company Overview 58
5.18.1 Bioindustry Park Silvano Fumero SpA Pipeline Products & Ongoing Clinical Trials Overview 58
5.19 Brigham and Women's Hospital Company Overview 59
5.19.1 Brigham and Women's Hospital Pipeline Products & Ongoing Clinical Trials Overview 59
5.20 Captis Biotechnology Inc Company Overview 60
5.20.1 Captis Biotechnology Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.21 Celcuity Inc Company Overview 61
5.21.1 Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 61
5.22 Celula Inc Company Overview 62
5.22.1 Celula Inc Pipeline Products & Ongoing Clinical Trials Overview 62
5.23 Ceres Nanosciences Inc Company Overview 63
5.23.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.24 Chronix Biomedical Inc Company Overview 64
5.24.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 64
5.25 Clarient Inc Company Overview 65
5.25.1 Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 65
5.26 ClavGen Therapeutics LLC Company Overview 66
5.26.1 ClavGen Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 66
5.27 Cleveland Diagnostics Inc. Company Overview 67
5.27.1 Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 67
5.28 Courtagen Life Sciences Inc Company Overview 68
5.28.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.29 Dana-Farber Cancer Institute Inc Company Overview 69
5.29.1 Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 69
5.30 Diazyme Laboratories Inc Company Overview 70
5.30.1 Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 70
5.31 Entopsis LLC Company Overview 73
5.31.1 Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 73
5.32 Eventus Diagnostics Inc (Inactive) Company Overview 74
5.32.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 74
5.33 Exact Sciences Corp Company Overview 75
5.33.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 75
5.34 Exiqon AS Company Overview 76
5.34.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 76
5.35 Exosomics Siena SpA Company Overview 77
5.35.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 77
5.36 Fahy Gurteen UK Ltd Company Overview 78
5.36.1 Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 78
5.37 French National Institute of Health and Medical Research Company Overview 79
5.37.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 79
5.38 Ganymed Pharmaceuticals AG Company Overview 80
5.38.1 Ganymed Pharmaceuticals AG Pipeline Products & Ongoing Clinical Trials Overview 80
5.39 Georgia Institute of Technology Company Overview 81
5.39.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 81
5.40 Gina-Life Diagnostics Ltd Company Overview 82
5.40.1 Gina-Life Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 82
5.41 GlycoZym USA Inc Company Overview 83
5.41.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 83
5.42 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 84
5.42.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 84
5.43 HealthTell Inc Company Overview 85
5.43.1 HealthTell Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.44 Hide and Seq Company Overview 86
5.44.1 Hide and Seq Pipeline Products & Ongoing Clinical Trials Overview 86
5.45 Hudson Institute of Medical Research Company Overview 87
5.45.1 Hudson Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 87
5.46 Ikonisys Inc Company Overview 88
5.46.1 Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 88
5.47 INEX Innovate Pte Ltd Company Overview 89
5.47.1 INEX Innovate Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
5.48 InterGenetics Inc Company Overview 90
5.48.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 90
5.49 InterVenn BioSciences Company Overview 91
5.49.1 InterVenn BioSciences Pipeline Products & Ongoing Clinical Trials Overview 91
5.50 Johns Hopkins University Company Overview 94
5.50.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 94
5.51 KIYATEC Inc Company Overview 98
5.51.1 KIYATEC Inc Pipeline Products & Ongoing Clinical Trials Overview 98
5.52 Lab Discoveries Ltd Company Overview 99
5.52.1 Lab Discoveries Ltd Pipeline Products & Ongoing Clinical Trials Overview 99
5.53 Laboratorios SALVAT SA Company Overview 100
5.53.1 Laboratorios SALVAT SA Pipeline Products & Ongoing Clinical Trials Overview 100
5.54 Louisville Bioscience Inc (Inactive) Company Overview 101
5.54.1 Louisville Bioscience Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 101
5.55 MabCure Inc Company Overview 102
5.55.1 MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 102
5.56 Massachusetts Institute of Technology Company Overview 103
5.56.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 103
5.57 MDNA Life Sciences Inc Company Overview 104
5.57.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 104
5.58 Metabolon Inc Company Overview 105
5.58.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 105
5.59 Milagen Inc Company Overview 106
5.59.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 106
5.60 MyCartis NV Company Overview 107
5.60.1 MyCartis NV Pipeline Products & Ongoing Clinical Trials Overview 107
5.61 Nagoya University Company Overview 108
5.61.1 Nagoya University Pipeline Products & Ongoing Clinical Trials Overview 108
5.62 Nanostics Inc Company Overview 109
5.62.1 Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 109
5.63 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 110
5.63.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 110
5.64 Olink Proteomics AB Company Overview 111
5.64.1 Olink Proteomics AB Pipeline Products & Ongoing Clinical Trials Overview 111
5.65 Olympia Diagnostics Inc Company Overview 112
5.65.1 Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 112
5.66 Oncgnostics GmbH Company Overview 113
5.66.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 113
5.67 Oncimmune (USA) LLC Company Overview 114
5.67.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 114
5.68 Oncology Venture U.S. Inc Company Overview 115
5.68.1 Oncology Venture U.S. Inc Pipeline Products & Ongoing Clinical Trials Overview 115
5.69 Orion Genomics LLC Company Overview 116
5.69.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 116
5.70 OTraces Inc Company Overview 117
5.70.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 117
5.71 Peregrine Pharmaceuticals, Inc. Company Overview 118
5.71.1 Peregrine Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 118
5.72 Peri Rx Inc Company Overview 119
5.72.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 119
5.73 Precision Biologics Inc Company Overview 120
5.73.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 120
5.74 Preora Healthcare Inc Company Overview 121
5.74.1 Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 121
5.75 Princess Margaret Cancer Centre Company Overview 122
5.75.1 Princess Margaret Cancer Centre Pipeline Products & Ongoing Clinical Trials Overview 122
5.76 Protagen AG Company Overview 123
5.76.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 123
5.77 Proteomika (Inactive) Company Overview 124
5.77.1 Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 124
5.78 Provista Diagnostics Inc Company Overview 125
5.78.1 Provista Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 125
5.79 Queen's University Belfast Company Overview 126
5.79.1 Queen's University Belfast Pipeline Products & Ongoing Clinical Trials Overview 126
5.80 Rosetta Genomics Ltd Company Overview 127
5.80.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 127
5.81 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 128
5.81.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 128
5.82 SomaLogic Inc Company Overview 129
5.82.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 129
5.83 Soricimed Biopharma Inc Company Overview 130
5.83.1 Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 130
5.84 Stage I Diagnostics Inc Company Overview 132
5.84.1 Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 132
5.85 StageZero Life Sciences Ltd Company Overview 133
5.85.1 StageZero Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 133
5.86 SurExam Life Science & Technology Co. Company Overview 134
5.86.1 SurExam Life Science & Technology Co. Pipeline Products & Ongoing Clinical Trials Overview 134
5.87 Taizhou ZECEN Biotech Co Ltd Company Overview 135
5.87.1 Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 135
5.88 Target Discovery Inc Company Overview 136
5.88.1 Target Discovery Inc Pipeline Products & Ongoing Clinical Trials Overview 136
5.89 Teva Pharmaceutical Industries Ltd Company Overview 137
5.89.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 137
5.90 The University of Manchester Company Overview 138
5.90.1 The University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 138
5.91 Tradewind BioScience Inc Company Overview 139
5.91.1 Tradewind BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 139
5.92 Treos Bio Inc Company Overview 140
5.92.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 140
5.93 University of Adelaide Company Overview 141
5.93.1 University of Adelaide Pipeline Products & Ongoing Clinical Trials Overview 141
5.94 University of Arkansas for Medical Sciences Company Overview 143
5.94.1 University of Arkansas for Medical Sciences Pipeline Products & Ongoing Clinical Trials Overview 143
5.95 University of California San Diego Company Overview 144
5.95.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 144
5.96 University of Chicago Company Overview 145
5.96.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 145
5.97 University of Montreal Company Overview 146
5.97.1 University of Montreal Pipeline Products & Ongoing Clinical Trials Overview 146
5.98 University of Pittsburgh Company Overview 147
5.98.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 147
5.99 University of South Florida Company Overview 148
5.99.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 148
5.100 University of Texas MD Anderson Cancer Center Company Overview 151
5.100.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 151
5.101 US Biomarkers Inc Company Overview 152
5.101.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 152
5.102 Vermillion Inc Company Overview 153
5.102.1 Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview 153
5.103 Vitruvian Biomedical Inc Company Overview 154
5.103.1 Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 154
5.104 Wistar Institute Company Overview 155
5.104.1 Wistar Institute Pipeline Products & Ongoing Clinical Trials Overview 155
5.105 Yale University Company Overview 156
5.105.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 156
5.106 ZORA Biosciences Oy Company Overview 158
5.106.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 158
6 Ovarian Cancer- Recent Developments 159
6.1 Oct 23, 2020: Mentice receives order of total SEK
7.1 million from ABBOTT 159
6.2 Oct 20, 2020: Prescient Therapeutics : September 2020 quarterly update and Appendix 4C 159
6.3 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality 161
6.4 Jun 25, 2020: SEC charges Novartis with FCPA violations 163
6.5 Jun 18, 2020: IncellDx files patent for CCL5/RANTES utility as a diagnostic, prognostic, and therapeutic biomarker in COVID-19 and other cytokine storm conditions 163
6.6 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation 164
6.7 May 27, 2020: At-home screening for ovarian, breast cancers is effective 164
6.8 May 15, 2020: Xencor to present data from four preclinical XmAb 2+1 bispecific antibody and cytokine programs at AACR Virtual Annual Meeting II 166
6.9 May 05, 2020: InMed and Almac Group developing improved cannabinoid production methods 166
6.10 May 04, 2020: StageZero Life Sciences announces enhanced relationship with Phleb-Finders 167
6.11 Apr 29, 2020: Cancer testing and diagnosis suffers sharp downturn, finds Diaceutics 167
6.12 Apr 24, 2020: TruSight Oncology family grows with liquid biopsy and high-throughput assay additions 168
6.13 Apr 16, 2020: Abbott reports first-quarter 2020 results 170
6.14 Mar 06, 2020: 2cureX is accelerating the commercialization of IndiTreat by signing two distributor agreements to prepare for launch in second half of 2020 172
6.15 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors 172
6.16 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 173
6.17 Feb 26, 2020: Adaptive Biotechnologies reports fourth quarter and full year 2019 financial results 175
6.18 Feb 25, 2020: TCS digitally transforms Qiagen’s global research platform to improve user experience with new digital capabilities 176
6.19 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director 177
6.20 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal 177
6.21 Feb 13, 2020: LabCorp announces 2019 fourth quarter and full year results and provides 2020 guidance 177
6.22 Feb 12, 2020: Teva reports fourth quarter and full year 2019 financial results 180
6.23 Feb 11, 2020: Myriad Submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer 188
6.24 Feb 11, 2020: Abbott Laboratories: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officer 188
6.25 Feb 06, 2020: BD announces results for 2020 first fiscal quarter; lowers fiscal 2020 guidance 189
6.26 Feb 06, 2020: Myriad announces leadership transition 190
6.27 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 191
6.28 Feb 05, 2020: UMass Amherst study aims to develop new test for BRCA-positive lactating moms 193
6.29 Jan 29, 2020: Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 194
6.30 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results 200
6.31 Jan 27, 2020: CMS expands coverage of next generation sequencing as a diagnostic tool for patients with breast and ovarian cancer 208
6.32 Jan 22, 2020: Myriad submits sPMA for myChoice CDx with Zejula in first-line platinum responsive advanced ovarian cancer 208
6.33 Jan 22, 2020: Abbott reports fourth-quarter 2019 results; announces strong forecast for 2020 209
6.34 Jan 22, 2020: Novartis establishes its new legal entity in Vietnam 211
6.35 Jan 21, 2020: InterVenn Biosciences expands work in glycoproteomics to successfully target a range of cancers and other indications 211
6.36 Jan 21, 2020: Adaptive announces preliminary unaudited revenue for full year 2019 211
6.37 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 212
6.38 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 212
6.39 Jan 13, 2020: Foundation Medicine appoints Ritesh Khullar as Chief Commercial Officer 213
6.40 Jan 08, 2020: ABBOTT LABORATORIES: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. 214
6.41 Jan 07, 2020: Clovis Oncology announces debt refinancing transaction 214
6.42 Jan 07, 2020: Clovis Oncology announces product revenues for the fourth quarter and full year 2019 215
6.43 Jan 06, 2020: 2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia 215
6.44 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020 216
6.45 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 216
6.46 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 216
6.47 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members 219
6.48 Dec 17, 2019: Vermillion and Einstein Medical Center Philadelphia announce the first patient enrolled in prospective National Clinical Study of Ovarian Cancer Risk detection methods in African American Women 220
6.49 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline 221
6.50 Dec 13, 2019: Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. 221
6.51 Dec 13, 2019: 2cureX presented progression in the IndiTreat immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 222
6.52 Dec 05, 2019: Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day 222
6.53 Nov 26, 2019: LabCorp appoints senior finance executive Jeffrey A. Davis to its Board of Directors 223
7 Appendix 225
7.1 Methodology 225
7.2 About GlobalData 229
7.3 Contact Us 229
